Medications for Bipolar Disorder: Mood Stabilizers and Other Options
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Medication treatment for bipolar disorder is organized around three distinct clinical objectives: controlling an acute manic or mixed episode, treating bipolar depression, and preventing future mood episodes. Lithium, selected antiseizure medications, and particular second-generation antipsychotics can all be effective, but they differ in their evidence, side effects, monitoring requirements, and approved indications. A medicine that helps during mania may offer little benefit during bipolar depression; one that prevents depressive recurrence may offer insufficient protection against mania. These differences are fundamental to a safe treatment plan. CANMAT VA
Choosing a bipolar medication means examining the diagnosis, current episode, past responses, physical health, other prescribed medicines, and the patient's preferences. Medication management is often long-term and includes monitoring the effects of treatment, reviewing side effects, and planning for recurrence. Psychotherapy, sleep support, and practical assistance remain important alongside medication. The broader clinical pathway is described in Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care. This guide examines medication options in detail, including their comparative clinical evidence and significant safety precautions. NIMH NICE
For additional clinical context, see Lithium for Bipolar Disorder: Benefits, Risks, and Monitoring.
What medications are used for bipolar disorder?
The principal categories are lithium; certain anticonvulsant medications, especially lamotrigine, valproate or divalproex, and sometimes carbamazepine; second-generation antipsychotics; and occasionally carefully selected adjunctive antidepressants. Some people use one medicine, while others need a combination. The phrase “mood stabilizer” describes a clinical role rather than a single pharmacological mechanism or a promise of effectiveness across all phases. Several antipsychotics also function as mood-stabilizing treatments in specific circumstances. CANMAT NIMHMED
Lithium has strong evidence for reducing recurrence and treating mania. Valproate is particularly relevant to manic episodes in certain patients, with important safety restrictions. Lamotrigine is most closely associated with reducing depressive relapse and has a role in some treatment pathways for bipolar depression, but it is not a treatment for acute mania. Antipsychotics must be distinguished by agent: quetiapine has evidence across multiple phases; risperidone and aripiprazole have important antimanic indications; lurasidone, lumateperone, and cariprazine have evidence in bipolar depression. The diagnostic subtype, age, and whether a medicine is used alone or with another drug must be considered before applying a recommendation. CANMAT NICE YILDIZ
At a glance: which medicine fits which phase?
For acute mania, guidelines identify antipsychotics such as quetiapine, risperidone, olanzapine, or aripiprazole and mood-stabilizing agents such as lithium as options, depending on clinical circumstances and the particular guideline. In a more severe or incompletely responsive episode, combining an antipsychotic with lithium or another appropriate mood-stabilizing treatment may be considered. Evidence from a large network meta-analysis of acute mania confirms that effectiveness and tolerability differ substantially among specific treatments; rankings from indirect comparisons are not individual prescriptions. VA NICE HUANG
For bipolar depression, the strongest randomized evidence supports certain agents rather than antipsychotics as a whole. Quetiapine, lurasidone, cariprazine, lumateperone, and the olanzapine–fluoxetine combination have been studied in particular bipolar depressive populations. Evidence for lithium and lamotrigine in acute depression must be distinguished from their maintenance value. The 2023 adult randomized-trial network meta-analysis highlights benefits, limitations, and differing adverse-effect burdens. YILDIZ CANMAT
For maintenance, the aim is fewer depressive, manic, hypomanic, or mixed recurrences across months and years. Lithium is an important long-term option. Lamotrigine, selected antipsychotics, valproate regimens, and combinations may be considered after reviewing previous episode polarity and response. A 2026 network meta-analysis evaluated 44 maintenance trials with more than 10,000 participants; these findings supplement, rather than displace, clinical guidance because trial selection, treatment dose, age, tolerability, and baseline risk all affect interpretation. FORNARO NICE
Why the diagnosis and episode history matter
Bipolar I disorder is defined by a history of at least one manic episode. Bipolar II disorder involves hypomania and major depressive episodes, without a history of full mania. Mania can produce severe functional impairment or require hospitalization, while hypomania has a different severity threshold. Bipolar II may nonetheless involve recurrent, disabling depression. Cyclothymic disorder and other specified bipolar presentations require their own longitudinal clinical evaluation. An ordinary mood swing, an isolated period of high energy, or a positive online questionnaire does not establish a bipolar diagnosis. NIMH NICE
Prescribing assessment considers the patient's full episode pattern, mixed features, psychosis, suicidal thoughts, sleep changes, substance exposure, and the effects on relationships and functioning. Clinicians review whether thyroid disease, stimulant exposure, substances, or other psychiatric conditions could account for symptoms. A single depressive presentation can obscure previous hypomania; equally, sleep loss or anxiety alone does not prove mania. For the complete diagnostic process, see How Is Bipolar Disorder Diagnosed? Clinical Assessment Explained. VA NIMH
Past treatment response is often as informative as a broad first-line list. Records should identify why each drug was prescribed, whether it helped mania or depression, how long it was used, what adverse effects occurred, and whether episodes returned after changes. The evaluation also includes kidney, thyroid, liver, cardiovascular, metabolic, and neurological conditions; current medicines and interactions; pregnancy considerations; age; access to monitoring; and the patient's goals. A shared decision documents the intended benefit and how success will be judged. NICE VA
Lithium: a major treatment with essential blood monitoring
Lithium has a long record of use in bipolar disorder and is strongly supported for maintenance, particularly prevention of manic recurrence. It is also an effective acute antimanic treatment. The evidence relating lithium to reduced suicidal behavior is clinically important but should be interpreted according to study design and does not amount to an individual guarantee. The choice balances efficacy against medical suitability, laboratory access, past response, and patient preference. NICE VA
Lithium requires measurement of its concentration in blood because its therapeutic and toxic concentrations can be relatively close. Kidney function, thyroid function, electrolytes, and calcium are among the usual monitoring considerations; an ECG or additional evaluation may be required in certain patients. The monitoring interval is most intensive after starting lithium or changing treatment and continues during maintenance. NICE specifies follow-up schedules and circumstances requiring increased frequency, while the prescribing label explains how blood sampling and toxic concentrations are interpreted. NICE LITHIUM
Increased thirst, frequent urination, fine tremor, nausea, and changes in weight may occur. Other concerns include hypothyroidism, impaired concentrating ability of the kidneys, calcium or parathyroid abnormalities, and longer-term kidney effects. Worsening tremor, confusion, unsteadiness, vomiting, diarrhea, or significant neurological changes can signal toxicity and require prompt assessment. Fluid loss from fever, dehydration, or gastrointestinal illness can increase risk even when the previously prescribed dose was stable. LITHIUM NICE
Certain nonsteroidal anti-inflammatory pain relievers, diuretics, and blood-pressure medicines affecting the renin–angiotensin system may increase lithium concentration. Changes in fluid intake and sodium balance can alter exposure. People using lithium should tell clinicians and pharmacists about new medicines, over-the-counter treatments, and relevant illnesses. A dose should never be doubled or changed independently to compensate for a missed tablet or a suspected interaction. LITHIUM NIMHMED
Lamotrigine: maintenance benefit and serious skin warnings
Lamotrigine is used particularly where prevention of depressive recurrence matters. Its U.S. labeling describes maintenance treatment for bipolar I after stabilization, while some professional guidelines also consider it in specific bipolar-depression strategies. It is not an established rapid treatment for acute mania. A 2024 systematic review reported benefit for maintenance compared with placebo and evidence supporting certain adjunctive uses during depression, with interpretation differing by study type and comparator. LAMOTRIGINE HAENEN CANMAT
A 2021 Cochrane review found that lamotrigine can help prevent recurrent mood episodes relative to placebo. Comparisons with lithium must account for differential protection against manic recurrence: lithium may be more protective against mania for certain patients, although lamotrigine can be better tolerated for some long-term outcomes. These results explain why a clinician considers episode polarity before selecting a medicine instead of treating both as interchangeable “mood stabilizers.” HASHIMOTO
The major safety warning is potentially life-threatening rash, including Stevens–Johnson syndrome and toxic epidermal necrolysis. Lamotrigine is usually increased slowly, and excessive starting doses or rapid escalation increase the danger. Valproate can markedly increase lamotrigine exposure and requires changes to the titration strategy. Any new rash during initiation needs immediate clinician advice; rash with blistering, mouth sores, fever, or systemic illness requires emergency assessment. LAMOTRIGINE
Estrogen-containing contraceptives and certain antiseizure medications can alter lamotrigine levels, and starting or stopping these products may require a supervised plan. A prolonged interruption may mean the original slow titration must be repeated. The correct response to missed doses depends on how many doses were missed and the particular regimen. People should consult their prescriber or pharmacist rather than restarting a former full dose themselves. LAMOTRIGINE
Valproate and divalproex: antimanic benefits and major reproductive risks
Valproate-based medicines, including divalproex, are used to treat mania in selected patients and may contribute to some maintenance plans. Their role in bipolar depression differs, and they are not a universal treatment for every bipolar presentation. Choice depends on previous episode response, liver health, blood-count concerns, concurrent drugs, and reproductive risks. Product-specific U.S. indications and national recommendations can differ from other countries' guidance. VA CANMAT VALPROATE
Valproate carries boxed safety warnings for severe liver injury, potentially fatal pancreatitis, and harm to the fetus. In-utero exposure is associated with congenital malformations and developmental risks. People who are pregnant, might become pregnant, or are planning a pregnancy need specialist risk–benefit counseling and a coordinated treatment plan. An unexpected pregnancy while using valproate warrants prompt contact with the prescribing clinician; abrupt unsupervised discontinuation can itself destabilize severe bipolar illness. VALPROATE NICE
Prescribers evaluate liver function, blood counts, side effects, and sometimes drug levels depending on the situation. Nausea, tremor, sedation, weight gain, hair changes, and reduced platelets may occur. Severe abdominal pain with vomiting, jaundice, unusual bleeding, or marked confusion requires urgent attention. Valproate interacts with lamotrigine in a way that raises the importance of careful dose titration and early investigation of skin symptoms. VALPROATE LAMOTRIGINE
Reproductive safety planning should take place before pregnancy becomes an urgent issue and should involve obstetric expertise when relevant. Restrictions on valproate differ internationally and have changed over time, including attention to potential risks associated with paternal exposure. The clinician should use current jurisdiction-specific requirements, label warnings, and the patient's circumstances rather than assuming one country's rule applies globally. NICE VALPROATE
Carbamazepine and why not every antiseizure medicine works
Carbamazepine has an antimanic evidence base but interacts with many medicines and can complicate the treatment of coexisting medical conditions. It can reduce the effectiveness of some hormonal contraceptives and change concentrations of other psychiatric drugs. Monitoring may involve blood counts, liver tests, sodium, and clinical checks for serious skin or hematologic reactions. Where appropriate, ancestry-informed genetic screening can help address known severe cutaneous adverse reaction risks. VA CANMAT
Antiseizure medication is a broad pharmacological category; it does not mean each agent is proven to treat bipolar disorder. NICE specifically recommends against gabapentin and topiramate for bipolar disorder. Descriptions of “natural alternatives” or “antiepileptic mood stabilizers” without a specific indication and evidence base can mislead a person about both efficacy and potential harm. NICE
Antipsychotics: important choices with different indications
Second-generation antipsychotics are used across bipolar care, but the agents are clinically distinct. Quetiapine is supported for several phases. Aripiprazole, risperidone, and olanzapine have antimanic roles; lurasidone, lumateperone, and cariprazine have bipolar-depression evidence in applicable populations and regimens. The olanzapine–fluoxetine combination is a distinct treatment studied for bipolar depression, not evidence that fluoxetine alone is broadly suitable. Evidence for one antipsychotic, one phase, or one age group should not automatically be transferred to another. CANMAT YILDIZ VA
During severe mania, an antipsychotic may help control intense activation, psychosis, agitation, and behavioral disorganization. A person with serious impairment in judgment may need close supervision and sometimes inpatient care. Acute intervention also includes reviewing substances, hydration, sleep, and medical explanations. The drug that was useful during a crisis should be reassessed after the episode for long-term benefits, adverse effects, and the need for continued treatment. NICE VA
Some antipsychotics can cause significant weight gain, abnormal glucose control, and adverse lipid changes. Others are more likely to cause restlessness or akathisia, sedation, dizziness, movement-related symptoms, changes in prolactin, or cardiac rhythm considerations. These risks differ markedly by medication and dose. Baseline and ongoing weight, blood pressure, glucose or HbA1c, lipids, symptom and movement assessments, and selected ECG tests form part of safe treatment where relevant. A medication with fewer metabolic effects may carry different tolerability problems, so comparisons require multiple dimensions. NICE CANMAT
Long-acting injectable antipsychotics can be considered for some people who prefer fewer administration dates or who have difficulty maintaining a regular oral regimen. Only particular formulations have bipolar maintenance evidence and indications. Oral tolerability, injection-related issues, follow-up access, and the patient's choices must be reviewed. An injection formulation does not eliminate the need for metabolic, neurological, and clinical monitoring. VA FORNARO
Which medicines treat bipolar depression?
Depressive episodes in bipolar illness may be long-lasting and severely impairing, and they require specific evidence-based management. A systematic review and network meta-analysis in The Lancet Psychiatry compared acute bipolar depression treatments across 101 randomized trials involving more than 20,000 adults. It found support for particular medicines while documenting important variation in response, acceptability, and adverse effects. This is evidence about an adult acute depressive phase, not an automatic recommendation for maintenance, childhood illness, or other diagnoses. YILDIZ
Quetiapine, lurasidone, cariprazine, lumateperone, and the olanzapine–fluoxetine combination have been examined in clinical trials, but differences in approval, adjunctive requirements, sedation, restlessness, weight effects, and bipolar subtype remain important. Lamotrigine may be helpful as an adjunct or for depressive recurrence, while its slow titration limits its usefulness when rapid relief is required. Lithium can be valuable within an overall bipolar plan, but the maintenance evidence does not by itself establish acute antidepressant superiority. For the symptoms and differential assessment of bipolar depression, see Bipolar Depression: Symptoms, Diagnosis, and Course. YILDIZ HAENEN NICE
Depression accompanied by racing thoughts, increased activity, agitation, or reduced need for sleep may involve mixed features. These symptoms change the clinical risk assessment and may influence how antidepressants and mood-stabilizing treatments are considered. Clinicians should also examine new insomnia, impulsivity, and other indicators of an emerging elevated-mood episode. More information appears in Bipolar Disorder With Mixed Features: Symptoms, Risks, and Diagnosis. CANMAT NICE
Antidepressants: potential benefit, switching concerns, and limits
Antidepressants are not automatically excluded from every bipolar treatment plan, but they are approached differently than in uncomplicated unipolar depression. Antidepressant monotherapy is generally not recommended for bipolar I depression because of concerns about treatment-emergent mood elevation and inadequate antimanic protection. Some guidelines allow selected adjunctive treatments after assessing mixed symptoms, rapid cycling, previous switching, past benefit, and available alternatives. Bipolar II treatment decisions also need diagnosis-specific evidence, including careful monitoring. CANMAT VA NICE
The research does not support an oversimplified claim that every antidepressant inevitably causes mania. A 2025 network meta-analysis of randomized trials found no statistically significant increased switching risk for a single studied antidepressant compared with placebo, but comparisons were limited and confidence in the evidence was low. Absence of statistical significance cannot establish safety for an individual, particularly a person with mixed features or a past drug-associated switch. In STEP-BD, adding a conventional antidepressant to a mood stabilizer did not yield a clear overall durable recovery advantage in the studied sample. OLIVA STEPBD
When an antidepressant is used, follow-up should look for less need for sleep, unusual energy, impulsivity, agitation, racing thoughts, and worsening instability, as well as whether depression improves. Adverse effects, interactions, and discontinuation symptoms must also be considered. A patient who notices activation should contact the care team promptly and should not independently discontinue a complex medication regimen based on a generic warning. NICE NIMHMED
Combination treatment and polypharmacy
Combination treatment may be appropriate for severe mania, recurrent episodes, or an inadequate response to an appropriate, monitored trial. Lithium plus an antipsychotic and selected valproate-antipsychotic combinations are examples used in particular circumstances. Combination benefit is linked to phase and patient selection; it does not mean that adding more medicines reliably produces more stability. Sedation, weight effects, interactions, laboratory requirements, and cumulative neurological effects can all increase with additional agents. VA NICE HUANG
Before adding another drug, clinicians review whether the episode and diagnosis have been correctly identified, a medicine has been tried for an adequate period, side effects have limited adherence, interactions have reduced efficacy, or sleep disruption and substance exposure are worsening symptoms. Each addition should have a recorded indication, outcome measure, and review point. Avoiding unnecessary polypharmacy can improve both safety and the person's ability to maintain treatment. NICE CANMAT
Monitoring medications: what patients can expect
Baseline evaluation is medication-specific. Lithium requires renal, thyroid, calcium, and blood-concentration monitoring; valproate raises liver, blood-count, and reproductive-safety issues; lamotrigine needs careful escalation and rash counseling; and antipsychotics often require metabolic and movement-related assessments. Depending on health status, pregnancy potential, age, and other medications, additional tests may be indicated. The exact schedule follows clinical guidance, product labeling, and the person's risks. NICE LITHIUM LAMOTRIGINE VALPROATE
Regular appointments should track mood, sleep, energy, functioning, medication tolerability, adherence difficulties, and safety. Some patients benefit from bringing a brief sleep log, a mood diary, a full medicine list, and specific examples of adverse effects. Monitoring has two connected aims: identifying treatment effectiveness and detecting problems before they become serious. Clinicians and patients can also agree on who will be contacted when new symptoms emerge between appointments. NICE VA
If suspected lithium toxicity, a serious lamotrigine rash, valproate-associated abdominal or liver symptoms, high fever with pronounced rigidity while taking an antipsychotic, or severe new psychiatric symptoms appear, the person needs urgent medical attention. Manic escalation with dangerous judgment, psychosis, inability to remain safe, or suicidal intent can require emergency assessment. If immediate safety is at risk, contact local emergency services or attend an emergency department. In the United States, the 988 Suicide & Crisis Lifeline is available for suicide-related or mental health crisis support, but it does not replace emergency services for imminent danger. LITHIUM LAMOTRIGINE VALPROATE NICE [SAMHSA]
How long should bipolar medication continue?
Many people with bipolar disorder benefit from long-term maintenance medication because recurrence remains possible after symptoms resolve. The individual decision reflects prior episodes, severity, time since the last episode, consequences of recurrence, treatment benefit, adverse effects, and patient preferences. Follow-up also addresses physical health and whether the regimen still matches the predominant pattern of illness. Medication may remain useful for many years, with periodic review rather than a once-for-all prescription. NICE VA
A systematic review of randomized maintenance trials found that continuing an effective medication reduced the risk of recurrence compared with discontinuation in the populations studied. Those trials differed by drug, follow-up period, withdrawal procedure, and patient selection, so the data do not imply that everyone who stops treatment will relapse. Rapid discontinuation, especially of lithium, can create important recurrence risks. Decisions to reduce or stop medication need an individualized plan and continuing observation. KISHI NICE
Someone may want a change because of pregnancy planning, persistent fatigue, high medication cost, sexual or metabolic adverse effects, kidney problems, or difficulty attending blood tests. Each is a valid topic for a substantive care review. A clinician can consider alternative medicines, formulations, additional support, and the safest transition method. Simply feeling well does not necessarily indicate that preventive medication is no longer contributing to wellness. Warning patterns are examined further in Early Warning Signs of Mania and Bipolar Relapse. NICE KISHI
Bipolar II disorder, children, older adults, and reproductive health
Evidence for bipolar II medication treatment is narrower in some areas than that for bipolar I, particularly because many drug trials enroll predominantly patients with bipolar I. Bipolar II can involve severe depression and meaningful impairment. Recommendations should state when evidence applies directly and when clinical judgment extrapolates from other populations. Anxiety, ADHD, substance use, and physical illness may complicate the plan but should not automatically be treated as identical conditions. CANMAT VA
In children and adolescents, medication decisions require specialized diagnosis, developmental assessment, and age-specific treatment evidence. Adult trial results and adult approval status do not automatically transfer to pediatric care. In older adults, kidney function, dehydration, interactions, balance, cardiovascular disease, and cognitive effects may change the safest approach. More frequent laboratory or clinical monitoring can be appropriate. NICE VA
Pregnancy and postpartum care requires psychiatric and obstetric coordination because untreated mania or depression and medication exposure both have potential harms. Valproate has particularly significant fetal and reproductive warnings; lithium, lamotrigine, and antipsychotics each require separate pregnancy-specific assessment. Pregnancy can alter blood concentrations and the need for monitoring. Planning before conception is helpful where possible, and unexpected pregnancy warrants prompt consultation rather than abrupt independent medication changes. VALPROATE NICE LAMOTRIGINE
Medication works within a broader treatment plan
Psychoeducation, structured psychological treatment, family involvement when appropriate, and strategies that protect daily routines can complement medication. These approaches can support understanding of early warning signs, relationships, adherence challenges, and coordinated responses to relapse. Their effectiveness varies by method and outcome, and medication remains important for many people, especially during mania and in preventing recurrence. The Bipolar Disorder: Symptoms, Types, Diagnosis, and Treatment guide provides the condition-level context. NICE VA
Disturbed sleep is both a possible symptom of mood episodes and a practical warning sign for some people. Medication choices may account for sleep effects, yet excessive sedation can itself undermine daily functioning. A stable sleep schedule, support during stressful transitions, and prompt assessment of changes often improve the overall treatment process. For condition-specific sleep evidence, see Bipolar Disorder and Sleep: Mood Episodes, Circadian Rhythms, and Prevention. NIMH NICE
Questions to take to a prescribing appointment
Ask which episode or recurrence pattern the medicine is intended to treat, what improvement can reasonably be expected, how long a trial should last, and when treatment will be reviewed. Ask about alternatives with different adverse-effect profiles, interactions with existing medicines, practical laboratory monitoring, pregnancy or contraception considerations, missed-dose instructions, and warning signs requiring urgent contact. A clearly recorded medication goal gives both the patient and the clinician a basis for evaluating benefit. NICE VA
When side effects interfere with life, describe the exact problem: fatigue, tremor, weight change, stomach symptoms, restless movements, emotional blunting, or difficulty concentrating. Some symptoms may result from ongoing mood illness rather than a medicine, so clinical evaluation matters. A safe plan can address adverse effects without assuming the only available choice is to tolerate them indefinitely or to stop every treatment immediately. NIMHMED NICE
Frequently asked questions
What is the best medication for bipolar disorder?
There is no single medicine with the strongest benefit and safety profile for every subtype and phase. Lithium is important for maintenance and mania, while selected antipsychotics, lamotrigine, and other agents have different roles. The most appropriate choice is based on the current episode, medical history, response, adverse-effect risk, and the person's goals. CANMAT NICE
Are mood stabilizers and antipsychotics the same thing?
“Mood stabilizer” is a functional clinical term. Lithium has a distinct pharmacological identity, lamotrigine and valproate are also used as antiseizure medicines, and certain antipsychotics serve bipolar mood-stabilizing purposes. Individual drugs may be more effective against elevated mood, depression, or recurrence. Categorizing a pill is less informative than knowing which outcome its evidence supports. VA CANMAT
Is lithium always better than an antipsychotic?
Treatment objective determines the comparison. Lithium has substantial maintenance evidence and requires blood and organ-function monitoring; certain antipsychotics can be effective for acute mania, bipolar depression, or maintenance depending on the agent. Some regimens combine both types after evaluation. The side-effect burden and clinical response matter as much as a class label. NICE FORNARO
Can bipolar disorder be treated with one medicine?
Yes, some people respond well to monotherapy, especially during stable maintenance. Others need a combination during severe episodes or after an incomplete response. A combination should have a specific rationale, with regular review of interactions and adverse effects. The number of medicines alone does not indicate whether a treatment is appropriate. VA NICE
Do bipolar medications change your personality?
Their clinical purpose is to reduce disruptive mood episodes and preserve functioning. Sedation, fatigue, cognitive slowing, restlessness, or emotional dulling can occur with some medicines and deserve assessment. Similar complaints may also reflect residual depression or other health problems. A clinician can help evaluate the cause and consider alternatives when needed. NIMHMED NICE
Do people with bipolar disorder have to take medicine forever?
Some need sustained prevention for many years. The length and combination of treatment should be reviewed individually in light of recurrence, tolerability, and goals. Discontinuation can increase relapse risk, particularly if abrupt; changes should be supervised and accompanied by a follow-up and warning-sign plan. KISHI NICE
Can antidepressants ever be used?
They are sometimes used as adjuncts in selected cases, but antidepressant monotherapy in bipolar I depression is generally discouraged. Clinicians review past switches, mixed symptoms, rapid cycling, prior responses, and the quality of the evidence. The potential risk of mania cannot be inferred from a single average trial estimate for all individuals. CANMAT OLIVA
What if I miss doses or develop a rash?
The response depends on the medicine, number of missed doses, and the symptoms involved. A serious new rash in a person using lamotrigine requires immediate clinical attention, and some treatment interruptions require restarting slow titration rather than resuming a full prior dose. Suspected lithium toxicity or severe systemic symptoms warrant urgent assessment. Contact the prescriber or pharmacist for medicine-specific instructions rather than doubling or abruptly restarting doses. LAMOTRIGINE LITHIUM
Related Articles
References
Fornaro, M., Di Lorenzo, C., Daray, F. M., & Kishi, T. (2026). Efficacy and safety of pharmacological interventions for the maintenance of bipolar disorder: A systematic review and dose-related network meta-analysis across different age groups. Journal of Affective Disorders, 407, 121798. DOI
Haenen, N., Kamperman, A. M., Prodan, A., Nolen, W. A., Boks, M. P., & Wesseloo, R. (2024). The efficacy of lamotrigine in bipolar disorder: A systematic review and meta-analysis. Bipolar Disorders, 26(5), 431–441. DOI
Hashimoto, Y., Kotake, K., Watanabe, N., Fujiwara, T., & Sakamoto, S. (2021). Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews, 9, CD013575. DOI
Huang, W., He, S., Liu, M., & Xu, J. (2025). Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: A systematic review and network meta-analysis of randomized controlled trials. Molecular Psychiatry, 30, 838–847. DOI
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. DOI
Kishi, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021). Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: A systematic review and meta-analysis. Psychological Medicine, 51(15), 2721–2729. DOI
National Institute for Health and Care Excellence. (2014, with subsequent updates). Bipolar disorder: Assessment and management (CG185). Official guideline
National Institute of Mental Health. (n.d.). Bipolar disorder. Official clinical overview
National Institute of Mental Health. (n.d.). Mental health medications. Official medication information
National Library of Medicine. (n.d.). Depakote (divalproex sodium): Official U.S. prescribing information. DailyMed. Product label
National Library of Medicine. (n.d.). Lamictal (lamotrigine): Official U.S. prescribing information. DailyMed. Product label
National Library of Medicine. (n.d.). Lithium carbonate: Official U.S. prescribing information. DailyMed. Product label
Oliva, V., et al. (2025). Switch to mania after acute antidepressant treatment for bipolar depression: A systematic review and network meta-analysis of randomised controlled trials. eClinicalMedicine, 87, 103413. DOI
Sachs, G. S., et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 356, 1711–1722. PubMed
Substance Abuse and Mental Health Services Administration. (n.d.). Crisis help: Suicide, mental health, drug, and alcohol issues. Official 988 and emergency resources
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of bipolar disorder. Official guideline
Yildiz, A., Siafis, S., Mavridis, D., Vieta, E., & Leucht, S. (2023). Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 10(9), 693–705. DOI